Temporal trends in the utilization of advanced therapies among patients with acute pulmonary embolism: insights from a national database

Eur Heart J Acute Cardiovasc Care. 2023 Oct 25;12(10):711-713. doi: 10.1093/ehjacc/zuad092.

Abstract

There is a paucity of data regarding the contemporary temporal trends in the adoption of advanced pulmonary embolism (PE) therapies in the United States as well as the parallel trends in outcomes of patients with acute PE. Therefore, we queried the Nationwide Readmissions Database (years 2016-2020) to report the temporal trends in utilization of advanced PE therapies. Our final analysis included 920 770 hospitalizations with acute PE. We demonstrated an increase in the proportion of patients diagnosed with high-risk PE during the study years. Overall, there was an increase in the use of advanced PE therapies, which was mainly due to the increase in the utilization of systemic thrombolytics, and catheter-directed therapies. Also, extracorporeal membrane oxygenation cannulation showed an incremental increase over the study years. The use of inferior vena cava filter has declined, while the use of surgical embolectomy did not change during the study years. The use of advanced therapies has increased among urban teaching, but not among urban non-teaching hospitals. During the study years, there was no change in unadjusted or adjusted in-hospital mortality rates among patients with acute PE, while the 90-day unplanned readmission rate has declined.

Keywords: Acute pulmonary embolism; Advanced therapies; High-risk PE; PERT.

MeSH terms

  • Acute Disease
  • Fibrinolytic Agents / therapeutic use
  • Hospitalization
  • Humans
  • Patient Readmission
  • Pulmonary Embolism* / diagnosis
  • Pulmonary Embolism* / epidemiology
  • Pulmonary Embolism* / therapy
  • Retrospective Studies
  • Thrombolytic Therapy
  • United States / epidemiology

Substances

  • Fibrinolytic Agents